Iain Ross has made an immediate mark on ReNeuron, overseeing a restructuring to reduce the British biotech’s head count by 40% within weeks of taking the reins. The cuts extend the stem cell player’s ...

Every investor in ReNeuron Group plc (LON:RENE) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see ...

ReNeuron has reported further improvements in the vision of patients treated with its cell therapy. The mean increase in visual acuity across the three retinitis pigmentosa (RP) patients now stands at ...

At the most recent follow-up, subjects in the study showed a mean improvement from baseline in visual acuity of + 23 letters in the treated eye. The untreated control eyes did not show meaningful ...

Angel Biotech (LON:ABH), the biopharmaceutical contract manufacturer, has signed a revised, longer-term contract with fellow AIM company Reneuron (LON:RENE) that will see it provide development and ...

Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi ...

LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k ...

ReNeuron’s investigational stem cell therapy has received orphan status in the EU and US for use in a rare eye disorder. Both the European Medicines Agency (EMA) and the Food and Drug Administration ...

LONDON, July 16, 2019 /PRNewswire/ -- ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced that it has expanded its intellectual ...

Biotech firm Reneuron Group has become the latest company to exit from the London Stock Exchange’s AIM as it continues to fight for its life after entering administration. The Welsh company, which was ...

(Reuters) - Biotechnology company ReNeuron Group Plc said its experimental stem cell therapy helped some patients improve motor functions in their arms in a mid-stage study after being disabled by ...